Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
28-day drospirenone contraceptive · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 28-day Desogestrel Oral Contraceptive | EXPERIMENTAL | - |
| 28-day Drospirenone Oral Contraceptive | ACTIVE_COMPARATOR | - |
| 28-day Levonorgestrel Oral Contraceptive | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Desogestrel/ethinyl estradiol and ethinyl estradiol | DRUG | Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet |
| 28-day drospirenone oral contraceptive | DRUG | Drospirenone/ethinyl estradiol 0.3/0.02 mg |
| 28-day levonorgestrel oral contraceptive | DRUG | Levonorgestrel/ethinyl estradiol 0.1/0.02 mg |
Inclusion Criteria: * Premenopausal, non-pregnant, non-lactating women age 18-35 years old * Body Mass Index (BMI) ≥18 kg/m² and \<30 kg/m² * Regular spontaneous menstrual cycle * Others as dictated by Food and Drug Administration (FDA)-approved protocol Exclusion Criteria: * Any condition which ...
28-day drospirenone contraceptive is an investigational small molecule being studied for its effects on follicle development. It is being evaluated in a clinical trial for ovarian follicular activity, follicle count, and follicle size in healthy female volunteers. The drug is in Phase 1 clinical development and is not yet approved.
28-day drospirenone contraceptive is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical research on this investigational oral contraceptive.
28-day drospirenone contraceptive is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
28-day drospirenone contraceptive was studied in a completed Phase 1 trial with NCT number NCT01291004. The trial evaluated ovarian follicular activity and hormone levels compared to two 28-day oral contraceptives, enrolling 206 healthy female participants in the United States.
Yes, 28-day drospirenone contraceptive is also known as DR-102. The clinical trial NCT01291004 refers to the drug as DR-102 when comparing it to two other 28-day oral contraceptives.